VirnetX Holding Corporation — 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020; filed March 16, 2021. This is an annual report, not a standalone fourth-quarter report. Financial amounts below are in U.S. dollars; amounts converted from thousands are identified as millions.
Business context
VirnetX develops and licenses patented secure-network communication technology, including its GABRIEL platform, Gateway and Collaboration Suite, with applications in zero-trust network access, 4G/5G and secure communications. Its business is centered on patent licensing and enforcement, with software and services at an early stage of commercialization. The company reported approximately 194 patents and pending applications. It said more than 80 small and medium-sized businesses had installed GABRIEL products, while product revenue remained limited.
Financial performance and position
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $302.636 million | $85,000 |
| Operating expenses | $144.743 million | $19.750 million |
| Income (loss) from operations | $157.893 million | $(19.665) million |
| Net income (loss) | $280.429 million | $(19.180) million |
| Diluted earnings (loss) per share | $3.92 | $(0.28) |
| Net cash from (used in) operations | $281.389 million | $(15.080) million |
- 2020 results were dominated by the $454.034 million Apple I payment collected in March. The company classified $302.428 million as royalty revenue, $41.271 million as a gain for willful infringement, $108.221 million as interest income and $2.114 million as reimbursement of litigation costs. It also recorded $90.101 million of licensing costs related to the proceeds.
- Reported operating margin was approximately 52% and net margin approximately 93%; both are heavily affected by this litigation-related, non-recurring event and should not be viewed as representative of ongoing operations.
- Research and development expense increased to $8.830 million from $3.845 million. Selling, general and administrative expense rose to $45.812 million from $15.905 million; legal fees were $30.699 million, versus $5.898 million.
- At year-end, cash and cash equivalents were $192.908 million and available-for-sale investments were $28.348 million, compared with $3.135 million and $2.394 million, respectively, a year earlier. Total current assets were $224.432 million; current liabilities were $10.356 million, including $9.438 million of accrued licensing costs. The balance sheet reports no debt.
- Operating cash flow was $281.389 million. Investing activities used $25.953 million, including net investment purchases; financing activities used $65.663 million, largely reflecting the $70.841 million one-time dividend. The dividend was $1 per share.
- Total assets were $234.793 million and stockholders’ equity was $224.437 million at year-end. The company sold 1,049,382 shares through its ATM offering for $4.627 million gross proceeds during 2020.
Material changes versus 2019
- Revenue and earnings shifted from minimal revenue and a net loss to substantial reported income, principally because VirnetX collected the Apple I judgment payment.
- Cash and investments increased significantly following the Apple payment. The company also paid a one-time dividend and continued issuing shares through its ATM program.
- Litigation and legal costs increased materially, as did research and development spending.
Outlook, commentary and key risks
- No numerical revenue, earnings or cash-flow guidance was provided. Management said existing cash and short-term investments should fund current operating levels, including legal expenses, for the foreseeable future. It expects future revenue to come primarily from patent licenses and royalties.
- VirnetX described commercialization and licensing growth as uncertain. It reported minimal revenue from licensing activities and limited revenue from GABRIEL products; prospective customers may defer agreements pending litigation outcomes, and sales cycles may be long.
- Apple II: a jury awarded VirnetX $502.8 million in October 2020 for infringement of two patents. The district court denied Apple’s post-trial motion in January 2021, but Apple appealed in February 2021. The award had not been collected as of the filing, and patent challenges could reduce, eliminate or delay it.
- VirnetX appealed patent invalidity findings in related Patent Trial and Appeal Board proceedings. The company warned that litigation and patent challenges could be costly and could impair its ability to license or enforce its portfolio. Some issued patents expire between 2020 and 2024.
- McKool Smith sought approximately $36.3 million, or 8% of the Apple I payment, in arbitration as a claimed contingency fee. VirnetX disputes the claim; a ruling was pending at the filing date.
- Other identified risks include dependence on a limited number of licensing and settlement sources, competition, regulatory and privacy requirements, cybersecurity and product risks, COVID-19 effects on sales and partnerships, and possible need for additional capital.
- The company reported a one-time $1-per-share dividend, not a commitment to recurring dividends. Its independent auditor gave unqualified opinions on the financial statements and internal control over financial reporting.
Important facts for investors to verify
- Current status, appeal timetable and enforceability of the $502.8 million Apple II verdict, including ongoing patent validity challenges.
- Resolution and financial impact of McKool Smith’s approximately $36.3 million fee claim, and any other litigation-related obligations.
- How much of future revenue comes from recurring licenses and products, rather than one-time settlements, and whether GABRIEL adoption is translating into material sales.
- Cash and investment balances, accrued licensing costs, legal spending and any future capital raising or share dilution.
- Remaining patent life and the commercial value of the portfolio as patents approach expiration.